Shire Plc (SHP), Ireland’s biggest drugmaker, is aiming to introduce a medicine that quells the urge to overeat. Just don’t call it a diet drug. After Alkermes Inc. (ALKS) last week stopped developing a similar medicine, Shire became the top candidate to develop the first approved drug to combat binge-eating disorder. The Dublin-based company says its treatment, Vyvanse, now marketed for hyperactivity, may limit binging by interacting with brain chemicals that affect mood, motivation and inhibition.
